Vanda Pharmaceuticals Inc. (LON:0LKB)
London
· Delayed Price · Currency is GBP · Price in USD 4.400
-0.120 (-2.65%)
At close: Feb 21, 2025
Vanda Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 198.77 | 192.64 | 254.38 | 268.68 | 248.17 | Upgrade
|
| Revenue Growth (YoY) | 3.18% | -24.27% | -5.32% | 8.27% | 9.23% | Upgrade
|
| Cost of Revenue | 11.31 | 14.8 | 24.28 | 25.63 | 23.36 | Upgrade
|
| Gross Profit | 187.46 | 177.84 | 230.1 | 243.05 | 224.8 | Upgrade
|
| Selling, General & Admin | 146.41 | 112.88 | 136.49 | 124.05 | 140.51 | Upgrade
|
| Research & Development | 74.43 | 76.82 | 85.77 | 75.36 | 55.58 | Upgrade
|
| Operating Expenses | 228.12 | 191.8 | 223.77 | 200.89 | 197.57 | Upgrade
|
| Operating Income | -40.66 | -13.95 | 6.33 | 42.17 | 27.24 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 4.42 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.75 | 11.49 | 2.01 | 1.85 | - | Upgrade
|
| EBT Excluding Unusual Items | -29.92 | -2.46 | 8.34 | 44.01 | 31.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | 6.99 | 8.8 | 2.96 | -1.65 | - | Upgrade
|
| Pretax Income | -22.92 | 6.34 | 11.3 | 42.36 | 31.66 | Upgrade
|
| Income Tax Expense | -4.02 | 3.83 | 5.03 | 9.21 | 8.32 | Upgrade
|
| Net Income | -18.9 | 2.51 | 6.28 | 33.15 | 23.34 | Upgrade
|
| Net Income to Common | -18.9 | 2.51 | 6.28 | 33.15 | 23.34 | Upgrade
|
| Net Income Growth | - | -60.02% | -81.07% | 42.06% | -79.80% | Upgrade
|
| Shares Outstanding (Basic) | 58 | 57 | 56 | 56 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 58 | 58 | 57 | 57 | 55 | Upgrade
|
| Shares Change (YoY) | 1.03% | 1.01% | 0.11% | 3.14% | 0.63% | Upgrade
|
| EPS (Basic) | -0.33 | 0.04 | 0.11 | 0.60 | 0.43 | Upgrade
|
| EPS (Diluted) | -0.33 | 0.04 | 0.11 | 0.58 | 0.42 | Upgrade
|
| EPS Growth | - | -63.64% | -81.03% | 38.10% | -80.09% | Upgrade
|
| Free Cash Flow | -20.48 | -88.25 | 31.31 | 63.66 | 49.98 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | -1.53 | 0.55 | 1.12 | 0.91 | Upgrade
|
| Gross Margin | 94.31% | 92.32% | 90.45% | 90.46% | 90.59% | Upgrade
|
| Operating Margin | -20.46% | -7.24% | 2.49% | 15.69% | 10.98% | Upgrade
|
| Profit Margin | -9.51% | 1.30% | 2.47% | 12.34% | 9.40% | Upgrade
|
| Free Cash Flow Margin | -10.30% | -45.81% | 12.31% | 23.69% | 20.14% | Upgrade
|
| EBITDA | -32.53 | -10.94 | 9.06 | 45.01 | 30.1 | Upgrade
|
| EBITDA Margin | -16.36% | -5.68% | 3.56% | 16.75% | 12.13% | Upgrade
|
| D&A For EBITDA | 8.13 | 3.01 | 2.73 | 2.84 | 2.86 | Upgrade
|
| EBIT | -40.66 | -13.95 | 6.33 | 42.17 | 27.24 | Upgrade
|
| EBIT Margin | -20.46% | -7.24% | 2.49% | 15.69% | 10.98% | Upgrade
|
| Effective Tax Rate | - | 60.42% | 44.47% | 21.74% | 26.28% | Upgrade
|
| Revenue as Reported | 198.77 | 192.64 | 254.38 | 268.68 | 248.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.